Maggot therapy

Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations

Retrieved on: 
Wednesday, April 26, 2023
Surgeon, Surgery, Takeda, GTCR, TAK, TachoSil, Takeda Pharmaceutical Company, Francisco Corzas, Acquisition, FDI, Patient, Maggot therapy, Growth, Health, Pharmaceutical industry

WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria. Corza Medical had previously acquired the commercial product rights for TachoSil, a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021. Corza Medical shares Takeda’s commitment to patient care and has the experience and resources to continue investing in TachoSil for the benefit of patients. 

Key Points: 
  • WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria.
  • Corza Medical had previously acquired the commercial product rights for TachoSil , a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021.
  • Corza Medical shares Takeda’s commitment to patient care and has the experience and resources to continue investing in TachoSil for the benefit of patients.
  • “We look forward to welcoming the Takeda TachoSil operations team to Corza Medical to support our investment in expanding manufacturing capacity, testing systems, and R&D facilities to develop new Biosurgery offerings,” said Tom Testa, Corza Medical Chief Executive Officer.

Corza Medical Expands Global Leadership Team

Retrieved on: 
Monday, January 9, 2023
Maggot therapy, Getty, Doctor of Philosophy, Surgery, Takeda Pharmaceutical Company, GE, GTCR, Simmons, Growth, Novena Global Lifecare, Cardinal Health, GE Healthcare, TachoSil, Senior, Leclercq, Management, Ophthalmology

WESTWOOD, Mass., Jan. 9, 2023 /PRNewswire/ -- Corza Medical has announced key additions to the global leadership team as the company builds for the next phase of growth.

Key Points: 
  • WESTWOOD, Mass., Jan. 9, 2023 /PRNewswire/ -- Corza Medical has announced key additions to the global leadership team as the company builds for the next phase of growth.
  • "Corza Medical is intensely focused on making every customer interaction remarkable, earning client's trust through our high-quality technologies, and delivering outstanding value.
  • With the foundation of Corza Medical now established, we are excited to announce the next level of leadership reporting to chief executive officer, Tom Testa," said Gregory T. Lucier, Executive Chairman of Corza Medical.
  • "Having built the foundation of the company the last two years, we are excited with these additions to our outstanding leadership team as we now move our focus to transformational growth," said Tom Testa, CEO of Corza Medical.

Corza Medical Expands Global Leadership Team

Retrieved on: 
Monday, January 9, 2023
Maggot therapy, Getty, Doctor of Philosophy, Surgery, Takeda Pharmaceutical Company, GE, GTCR, Simmons, Growth, Novena Global Lifecare, Cardinal Health, GE Healthcare, TachoSil, Senior, Leclercq, Management, Ophthalmology

WESTWOOD, Mass., Jan. 9, 2023 /PRNewswire/ -- Corza Medical has announced key additions to the global leadership team as the company builds for the next phase of growth.

Key Points: 
  • WESTWOOD, Mass., Jan. 9, 2023 /PRNewswire/ -- Corza Medical has announced key additions to the global leadership team as the company builds for the next phase of growth.
  • "Corza Medical is intensely focused on making every customer interaction remarkable, earning client's trust through our high-quality technologies, and delivering outstanding value.
  • With the foundation of Corza Medical now established, we are excited to announce the next level of leadership reporting to chief executive officer, Tom Testa," said Gregory T. Lucier, Executive Chairman of Corza Medical.
  • "Having built the foundation of the company the last two years, we are excited with these additions to our outstanding leadership team as we now move our focus to transformational growth," said Tom Testa, CEO of Corza Medical.

Global Biosurgery Market Report to 2027 - Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022
Surgery, Health, Plastic surgery, Prostate cancer, Cancer, Infection, Sealant, Stroke, Pain, Competitive landscape, COVID-19, General surgery, Adhesion, Hospital, Baxter International, Acquisition, Coronary artery disease, Growth, Wound healing, Integra, British Heart Foundation, Bleeding, Degenerative disease, RTI, BD, Pfizer, Incidence, RTI Surgical, Retail, Beauty salon, Dietary supplement, Dentistry, Maggot therapy, Hemostat, Geography

The "Biosurgery - Global Market Insights, Competitive Landscape and, Market Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosurgery - Global Market Insights, Competitive Landscape and, Market Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2022-2027.
  • Key Takeaways from the Biosurgery Market Report Study:
    The effect of the COVID-19 pandemic on this market is significant.
  • To capture and analyze suitable indicators, our experts are closely watching the biosurgery market
    Key companies dominating the global biosurgery market.

UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Marketing, Strategic planning, Hemostasis, Nasdaq, St. Lawrence University, Technology, Board, Solution, Board of directors, Johnson & Johnson, Company, Neoplasm, Patient, Mitomycins, Surgeon, Worldwide, Boston Scientific, Economics, Fine chemical, Pharmaceutical industry, Management, Medicine, Maggot therapy, Ethicon Inc.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dan Wildman to its Board of Directors, effective immediately.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dan Wildman to its Board of Directors, effective immediately.
  • Dan Wildman, Chairman of the Board of Progenerative Medical, Inc., a 40-year veteran of the medical device industry, and Strategic Advisor to several medical device and pharmaceutical companies, has agreed to join UroGens board, effective immediately.
  • We are pleased to welcome Dan Wildman to UroGens Board of Directors, said Liz Barrett, President and Chief Executive Officer, UroGen.
  • I am impressed with UroGens innovative technology and its potential to disrupt other areas of urologic oncology, said Dan Wildman.

Ganymed Robotics Appoints Michel Therin and Mike Lobinsky on its Board of Directors

Retrieved on: 
Thursday, September 1, 2022
Software, Radiology, Hardware, Data Management, Technology, Medical Devices, Health Technology, Surgery, Cardiology, Biotechnology, Audio, Video, Other Technology, Health, EOS, Wilco, CEO, Technology, Organizational founder, Research, Lists of people executed in the United States, Artificial intelligence, Smith, Robotics, EOS imaging, Judgement, Board, Director, Intelligence, Elective surgery, Corindus Vascular Robotics, Leadership, Maggot therapy, Independent Board for Presbyterian Foreign Missions, BAE Systems Electronic Systems, General surgery, News, Algorithm, Stryker, Siemens Healthineers, Medtronic, Efficiency, Advanced Therapy Medicinal Product, Industry, Acquisition, Ministry of Education (Malaysia), Patient, Management, Medical device, 3D printing, Ganymed, Covidien

Ganymed Robotics , a developer of computer vision algorithms and robotics technologies for orthopedic surgeons, announced it has appointed Michel Therin as Chairman of the Board of Directors and Mike Lobinsky as Independent Board Member.

Key Points: 
  • Ganymed Robotics , a developer of computer vision algorithms and robotics technologies for orthopedic surgeons, announced it has appointed Michel Therin as Chairman of the Board of Directors and Mike Lobinsky as Independent Board Member.
  • Aside of its role as Chairman of Ganymed, Michel also serves as a Member of the Board of Directors of Tissium, Keranova, SafeHeal, Affluent Medical and Betaglue Technologies.
  • Mike Lobinsky is an accomplished medical technology executive with more than 20 years of experience in the orthopedics and surgical robotics industry.
  • Sophie Cahen, CEO and Cofounder of Ganymed Robotics, said: The arrival of Michel and Mike on our Board is terrific news as we are expanding our technology platform and preparing for commercialization.

Verastem Oncology Appoints Michelle Robertson to Board of Directors

Retrieved on: 
Tuesday, October 26, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Science, Biotechnology, RAS, Cancer, Momenta, Security (finance), U.S. Securities and Exchange Commission, Patient, Editas Medicine, Ironwood Pharmaceuticals, FAK, Baxter International, SEC, Oncology, Maggot therapy, Leadership, Genzyme, Bentley University, Commercial Operating System (COS), Johnson & Johnson, Patent, Company, Board, Government, Acquisition, BS, Shire, Director, Board of directors, Pharmaceutical industry

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of Michelle Robertson to its Board of Directors, effective November 15, 2021.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of Michelle Robertson to its Board of Directors, effective November 15, 2021.
  • We are immensely appreciative of Ginas many important contributions to Verastem during her tenure on the Board, and we look forward to welcoming Michelle as Verastem continues to rapidly advance its development program in RAS targeted treatment, said Michael Kauffman, M.D., Ph.D., Lead Director of the Verastem Oncology Board of Directors.
  • Michelles extensive leadership in Finance and Commercial Operations for leading biotechnology companies will be an asset to our Board.
  • Verastems work to bring new treatment options to patients with RAS pathway-driven cancers is inspiring, and I am energized to join the Board of Directors at such an exciting time, said Ms. Robertson.

Medaxis Releases report highlighting consequences of poor wound debridement

Retrieved on: 
Thursday, April 23, 2020
Medicine, Clinical medicine, Branches of biology, Debridement, Wound, Wound bed preparation, Maggot therapy

Debridement is a medical procedure where the dead or infected tissue is removed from a wound to promote wound healing.

Key Points: 
  • Debridement is a medical procedure where the dead or infected tissue is removed from a wound to promote wound healing.
  • The goal of debridement is to kick-start the wound healing process.
  • For more details on the value of a good debridement, the Medaxis white paper can be found here .
  • Located in Zug, Switzerland, Medaxis is a Swiss-owned wound care company specializing in the application of micro water jet technology in wound care.

Aroa Biosurgery Launches Large Format Endoform® to Treat Larger, More Complex Wounds

Retrieved on: 
Friday, February 7, 2020
Research, Surgery, Medical devices, Medical Supplies, Biotechnology, Other Health, Health, Other Science, Science, Medicine, Clinical medicine, Medical specialties, Chronic wound, Necrosis, Venous ulcer, Maggot therapy, Ulcer, Extracellular matrix, Aroa

Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has now launched a large format version of its Endoform Natural product.

Key Points: 
  • Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has now launched a large format version of its Endoform Natural product.
  • Aroa Chief Executive, Brian Ward said this large format version of Endoform Natural addresses the growing need to treat large wounds with a single sheet of their extracellular matrix-based product and provides more options for clinicians.
  • This format is also suitable for wounds such as chronic wounds and venous leg ulcers.
  • Aroa intends to make the large format available in a range of global markets as and when regulatory approvals are granted.

EO2 Announces Publication in Wounds of Positive Impact of Debridement from Randomized Clinical Trial in Treatment of Diabetic Foot Ulcers

Retrieved on: 
Thursday, September 19, 2019
Medicine, Clinical medicine, Health, Diabetes, Foot diseases, Diabetic foot ulcer, Wound, Debridement, Diabetic foot, Ulcer, Arterial insufficiency ulcer, Maggot therapy

The latest study, published in this month's Wounds journal, evaluates the positive impact continuous diffusion of oxygen (CDO), with the wearable EO2 Oxygen Delivery System (EO2 System), has on patients suffering from diabetic foot ulcers when coupled with frequent wound debridement.

Key Points: 
  • The latest study, published in this month's Wounds journal, evaluates the positive impact continuous diffusion of oxygen (CDO), with the wearable EO2 Oxygen Delivery System (EO2 System), has on patients suffering from diabetic foot ulcers when coupled with frequent wound debridement.
  • Sites that debrided ulcers in nearly every visit experienced a 240% improvement in the treatment arm over the placebo arm, supporting the importance of debridement as a component of the overall diabetic foot ulcer treatment strategy.
  • "This builds on the body of evidence that aggressive debridement facilitates wounds healing."
  • Does Debridement Improve Clinical Outcomes in People with Diabetic Foot Ulcers Treated With Continuous Diffusion of Oxygen?